ImmunoCellular Therapeutics. Ltd. Company Profile

11:48 EDT 22nd March 2018 | BioPortfolio

News Articles [740 Associated News Articles listed on BioPortfolio]

Public preferred share offering nets $4.65mm for ImmunoCellular Therapeutics

ImmunoCellular Therapeutics Ltd. (cancer immunotherapies) netted $4.65mm through a public offering of 5k Series B mandatorily convertible preferred shares priced at $1k apiece. Each share converts to ...

ImmunoCellular Therapeutics (IMUC) Presents At Lytham Partners Virtual Investor Conference - Slideshow

ImmunoCellular Therapeutics' (IMUC) CEO Anthony Gringeri on Q4 2017 Results - Earnings Call Transcript

ImmunoCellular Therapeutics' (IMUC) CEO Anthony Gringeri on Q3 2017 Results - Earnings Call Transcript

Synlogic Taps Andrew Gengos for Chief Operating Officer Post

Andrew Gengos has been named chief operating officer and head of corporate development for Cambridge, MA, biotech Synlogic (NASDAQ: SYBX). Gengos was most recently president and CEO of Westlake Villag...

Global Veterinary Therapeutics Market to Mark CAGR of 6.0% Over Next 10 Years - announces publication of its recently generated research report titled, "GlobalVeterinary Therapeutics MarketBy Type (Therapeutics Drugs, Therapeutics Vaccines, Feed Additives The...

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other di...

PubMed Articles [407 Associated PubMed Articles listed on BioPortfolio]

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Introduction to Volume 2 of JOPT Special Issue.

Introduction to Volume 1 of JOPT Special Issue.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [134 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1201 Associated Companies listed on BioPortfolio]

ImmunoCellular Therapeutics, Ltd. and BioWa, Inc.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "ImmunoCellular Therapeutics. Ltd." on BioPortfolio

We have published hundreds of ImmunoCellular Therapeutics. Ltd. news stories on BioPortfolio along with dozens of ImmunoCellular Therapeutics. Ltd. Clinical Trials and PubMed Articles about ImmunoCellular Therapeutics. Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunoCellular Therapeutics. Ltd. Companies in our database. You can also find out about relevant ImmunoCellular Therapeutics. Ltd. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record